Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain, José Baselga, Sung‐Bae Kim, Jungsil Ro, Vladimir Semiglazov, Mario Campone, Eva Ciruelos, Jean-Marc Ferrero, Andreas Schneeweiß, Sarah Heeson, Emma Clark, Graham Ross, Mark Benyunes, Javier Cortés

New England Journal of Medicine, 2015

MedStar Washington Hospital Center, Memorial Hospital, Memorial Sloan Kettering Cancer Center, University of Ulsan, Ulsan College, Asan Medical Center, Breast Cancer Research Foundation, Institute of Oncology NN Petrov, Research Institute Hospital 12 de Octubre, Centre Antoine Lacassagne, University Hospital Heidelberg, Heidelberg University, National Center for Tumor Diseases, Roche (United Kingdom), Hebron University, Vall d'Hebron Institute of Oncology

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2096

Citations

View on Google Scholar

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back